Endometrial cancer is one of the most common gynecologic malignancies, and while immune checkpoint inhibitors have changed the treatment landscape for some patients, responses remain unpredictable. The central problem, the authors note, is heterogeneity: tumors differ widely in their immune landscapes, and validated biomarkers that connect a tumor’s intrinsic biology to its surrounding immune environment are still scarce. The team, led by Genyi Jiang and corresponding author Bilan Li of the Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, set out to close that gap by mining multi-omics data for immune-related prognostic factors.

The computational backbone of the study was an integrative analysis of the TCGA-UCEC cohort, the largest public genomic dataset for endometrial carcinoma. Rather than examining messenger RNA in isolation, the researchers constructed a multi-omics framework that coupled hub genes with transcription factor associations, microRNA regulation, DNA methylation sites, and somatic mutation features across candidate modules, including a black module containing DDX58 and RSAD2 and additional blue, brown, and red modules enriched for immune signaling genes such as CD8A, CXCR3, CD74, and HLA-A. The resulting multi-omics score stratified patients by survival and by distinct immune features, and RSAD2 emerged as a molecule whose high expression tracked with adverse survival and with macrophage-related immune signatures.

RSAD2, short for Radical S-adenosyl methionine domain-containing protein 2, is an interferon-stimulated gene, meaning its expression surges when cells detect viral infection or inflammatory signals. That lineage gave the team a plausible mechanistic question: could an antiviral protein, chronically activated within the tumor, be doing more than reflecting inflammation? To find out, the researchers turned to gain- and loss-of-function experiments in endometrial cancer cell lines, forcing RSAD2 expression upward in some cells and silencing it with short hairpin RNAs in others.

The results were consistent across multiple assays. Overexpression of RSAD2 enhanced cancer cell proliferation, migration, and invasion, and increased both colony formation in two-dimensional culture and sphere formation in three-dimensional culture, a proxy for stem-like tumor behavior. In a xenograft mouse model, tumors engineered to overproduce RSAD2 grew faster. Knocking the gene down produced the opposite effects: reduced EdU staining for proliferation, fewer cells crossing Transwell membranes in migration and invasion assays, smaller and fewer spheroids, and lower viability in CCK-8 assays measured over time. Together, these experiments positioned RSAD2 not as a passive marker but as a functional driver of malignant phenotypes in vitro and in vivo.

To trace how RSAD2 exerts these effects, the team performed bulk RNA sequencing after RSAD2 knockdown and analyzed the differentially expressed genes through Gene Ontology and KEGG pathway frameworks. The transcriptomic signature pointed toward activation of the RAF–MEK–ERK cascade, a core arm of the MAPK signaling pathway that governs cell growth and survival. Western blotting confirmed the biochemical readout: the ratios of phosphorylated RAF1, MEK1/2, and ERK1/2 to their total protein levels shifted in concordance with RSAD2 expression, and the downstream immune-checkpoint protein PD-L1 moved in parallel, rising with RSAD2 overexpression and falling with knockdown. Among the upregulated genes was CXCL1, a chemokine known to signal through the CXCR1 and CXCR2 receptors expressed on myeloid cells.

The chemokine connection proved central. Quantitative RT-PCR and ELISA assays showed that CXCL1 expression and secretion changed in step with RSAD2 levels, and that this coupling was preserved under inflammatory stimulation. Single-cell RNA sequencing of integrated public datasets spanning normal endometrium, atypical endometrial hyperplasia, and endometrioid endometrial carcinoma placed RSAD2 expression in context alongside myeloid markers such as ITGAM and AIF1, hinting at a spatial relationship between RSAD2-high epithelial cells and myeloid populations as tissue progresses toward malignancy.

The functional test of tumor–macrophage communication followed a logic of conditioned media and co-culture. When the researchers exposed THP-1-derived macrophages to conditioned medium from RSAD2-overexpressing endometrial cancer cells, the macrophages showed enhanced chemotaxis, migrating more vigorously toward the tumor-derived signal, and mounted a mixed activation-associated transcriptional response. Critically, adding SX-517, an inhibitor of the CXCR1/2 receptors, attenuated both the migration and the transcriptional shift, implicating the CXCL1–CXCR1/2 axis as the conduit through which RSAD2-high tumors communicate with macrophages. In many solid tumors, tumor-associated macrophages occupy a spectrum between anti-tumor inflammatory states and pro-tumor states that suppress immunity and remodel tissue; a chemokine-driven recruitment program that tilts that balance would fit the adverse survival signal seen in the clinical data.

The translational dimension came from a retrospective cohort of 254 endometrial cancer patients treated at the authors’ institution, with ethics approval from the Shanghai First Maternity and Infant Hospital institutional review board and informed consent from all participants. Immunohistochemistry and multiplex immunohistochemistry on tumor sections showed that RSAD2 expression was elevated in endometrial cancer tissue compared with controls, correlated with immune-cell infiltration, and associated with poorer survival outcomes in univariable analyses. The clinical staining thus closed the loop that the TCGA analysis had opened: the same molecule flagged computationally as a risk factor could be visualized in patient tissue, colocalized with immune populations, and tied to outcome.

The authors are careful about scope. Their conclusion frames RSAD2 as a candidate biomarker of endometrial cancer progression and supports a potential role for RSAD2-associated CXCL1–CXCR1/2 signaling in tumor–macrophage communication, while explicitly stating that further ligand-specific, genetic, and immune-competent validation is required to establish mechanistic and translational significance. The experiments relied in part on immortalized cell lines and a THP-1 macrophage model, and the xenograft system lacks a fully intact immune system, so the immunology of the axis remains to be proven in immune-competent settings. Whether CXCR1/2 inhibition could complement existing immunotherapies in endometrial cancer is an obvious next question, as is whether RSAD2’s interferon-driven expression reflects chronic viral mimicry or another inflammatory trigger within the tumor microenvironment. What the study delivers now is a well-supported hypothesis with a molecular address: a biomarker linking a tumor’s intrinsic inflammatory state to the macrophages that surround it, and a signaling axis that drug developers have already learned to inhibit.

Subject of Research: RSAD2-associated CXCL1–CXCR1/2 signaling in tumor–macrophage communication and endometrial cancer progression

Article Title: Integrative multi-omics analysis implicates RSAD2-associated CXCL1–CXCR1/2 signaling in tumor–macrophage communication and progression of endometrial cancer

Article References: Jiang, G., Zhang, Y., Ding, Y., Cao, M., Kang, L., Sun, Y., Yan, J., Zhang, Y., Luo, J., Zhou, X., Wu, H., & Li, B. (2026). Integrative multi-omics analysis implicates RSAD2-associated CXCL1–CXCR1/2 signaling in tumor–macrophage communication and progression of endometrial cancer. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09080-3

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09080-3

Keywords: endometrial cancer, RSAD2, CXCL1, CXCR1/2, tumor-associated macrophages, tumor microenvironment, multi-omics, RAF-MEK-ERK, chemokine signaling, immunotherapy biomarkers, TCGA-UCEC, xenograft model

The tousled-like kinases take their name from the tousled phenotype observed in mutant Arabidopsis plants, and they have long been known to participate in DNA replication, chromatin assembly, and the cellular response to DNA damage. What remained unclear was how their molecular profiles vary across the full spectrum of human cancers and whether that variation carries clinical weight. To answer this, the research team integrated multi-omics data from The Cancer Genome Atlas, or TCGA, and the Genotype-Tissue Expression project, GTEx, covering 33 distinct cancer types. This design allowed them to compare tumor expression against matched normal tissue, track genetic alterations, and correlate kinase activity signatures with survival, genomic instability metrics, and immune infiltration patterns in a single coherent framework.

The first major finding is that TLK1 and TLK2, despite their close family relationship, behave very differently depending on the cancer. Their expression patterns diverge across tumor types, and their association with patient prognosis is cancer-type-specific rather than universal. This distinction matters because it cautions against treating the pair as interchangeable. Genetic alterations in both genes were frequently observed across the cohort, and those alterations correlated significantly with multiple canonical markers of genomic instability, including tumor mutation burden, microsatellite instability, and homologous recombination deficiency. In practical terms, tumors leaning on TLK signaling appear to be the ones tolerating, and perhaps accumulating, the kind of DNA-level chaos that drives malignancy and shapes treatment response.

Correlation alone rarely settles a biological question, so the team turned to functional experiments in cancer cell lines. When the researchers knocked down TLK1 or TLK2, the consequences were immediate and severe: DNA damage rose markedly, cellular proliferation faltered, and the cells underwent apoptosis. Interestingly, the two kinases were not redundant. TLK2 exhibited a more prominent role in DNA repair processes, suggesting that it carries a disproportionate share of the genome-maintenance workload. This kind of mechanistic separation is exactly what drug developers look for, because it implies that inhibitors could be tuned to disrupt repair machinery in tumors that depend on it most, a strategy already validated by the clinical success of PARP inhibitors in homologous recombination-deficient cancers.

Perhaps the most provocative portion of the study concerns the tumor microenvironment. TLK1 and TLK2 expression were both negatively correlated with immune and stromal scores, a pattern typically seen in tumors that keep immune cells at arm’s length. Digging deeper with computational deconvolution of immune cell composition, the researchers found that kinase expression was positively associated with resting CD4-positive T cells and macrophages but negatively associated with CD8-positive T cells and activated natural killer cells, the two cell populations most responsible for killing tumor cells. In other words, high TLK signaling coincided with an immune infiltrate that looks present but disarmed, dominated by bystander and suppressive populations rather than cytotoxic effectors.

Additional functional immune analyses sharpened this picture in an unexpected way. TLK1 and TLK2 expression correlated positively with immune exclusion signatures and with infiltration by myeloid-derived suppressor cells, or MDSCs, but not with the classical markers of T-cell exhaustion that have dominated immunotherapy research for the past decade. This is a meaningful distinction. Exhausted T cells are present in the tumor but functionally worn out, and checkpoint inhibitors can sometimes revive them. Excluded T cells, by contrast, never reach the tumor in force. The implication is that TLK-high tumors may resist immunotherapy not by tiring out their attackers but by building a physical and cellular barrier that keeps those attackers outside, with MDSCs acting as gatekeepers.

To confirm that these computational associations reflect real biology, the team performed multiplex immunohistochemistry on colorectal cancer tissue, and the results resolved the two kinases into strikingly divergent phenotypes. Tumors with high TLK1 showed reduced T cell infiltration, consistent with the immune exclusion signature seen in the pan-cancer data. Tumors with high TLK2 told a different story: they were enriched for regulatory T cells, the Tregs that actively suppress antitumor immunity, and showed upregulation of CD39, an ectoenzyme that degrades extracellular ATP into immunosuppressive adenosine. TLK1-high tumors, in short, wall out the immune system, while TLK2-high tumors invite in cells that shut it down. Two kinases, two distinct mechanisms of immune evasion.

The clinical payoff of this work lies in prediction. The authors report that TLK1 and TLK2 expression demonstrated predictive utility for responses to chemotherapy and immunotherapy across several malignancies. If validated prospectively, a simple measurement of kinase expression could help oncologists decide which patients are likely to benefit from checkpoint blockade and which might do better with alternative regimens, or with combinations designed to overcome the specific immune barrier a tumor has built. For TLK2-high tumors with Treg enrichment and CD39 upregulation, for example, pairing a TLK inhibitor with agents targeting adenosine signaling or Treg depletion becomes a testable, mechanistically grounded hypothesis.

None of this means a TLK-targeted drug is imminent. Kinase inhibitors must clear formidable hurdles of selectivity, and the functional experiments here were conducted in cell lines rather than in patients, so the causal chain from kinase inhibition to immune reactivation in living tumors remains to be demonstrated. The study is also, at its core, an observational atlas: it establishes robust associations across thousands of tumors and supports them with mechanistic experiments, but it does not yet show that blocking TLK1 or TLK2 in humans improves outcomes. What it does provide is a comprehensive, multi-omics rationale for pursuing those experiments, complete with biomarker hypotheses that can be tested in existing trial cohorts and tissue archives.

Still, the broader message is hard to ignore. Genomic instability and immune evasion are usually studied as separate chapters of cancer biology, yet this analysis ties them together through a single pair of DNA-repair kinases whose overexpression appears to let tumors both accumulate mutations and hide the resulting neoantigens from cytotoxic lymphocytes. As sequencing of tumors becomes routine and pan-cancer datasets grow, enzymes like TLK1 and TLK2 that sit at the junction of these processes are likely to attract increasing attention from translational researchers. For now, the tousled-like kinases have earned a place on the shortlist of targets that could link the integrity of the genome to the visibility of the tumor, and that link may prove to be one of the more consequential therapeutic openings in precision oncology.

Subject of Research: Pan-cancer roles of the TLK1 and TLK2 kinases in genomic instability, DNA repair, and tumor immune modulation

Article Title: A pan-cancer analysis of TLK1 and TLK2: genomic instability, immunomodulation, and therapeutic implications

Article References: Luo, F., Tan, J., Liu, Q., Wei, L., Liu, P., & Wu, C. (2026). A pan-cancer analysis of TLK1 and TLK2: genomic instability, immunomodulation, and therapeutic implications. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03290-w

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03290-w

Keywords: TLK1, TLK2, tousled-like kinases, pan-cancer analysis, genomic instability, DNA damage response, tumor microenvironment, immune exclusion, myeloid-derived suppressor cells, regulatory T cells, immunotherapy biomarkers, precision oncology

The research team, led by Chao Yu and Siyu Liu with corresponding authors Yakun Wang and Xiaotian Zhang, assembled a cohort of 563 patients with stage III or IV gastric cancer or gastroesophageal junction adenocarcinoma, all of whom had paired tumor and normal tissue analyzed by targeted sequencing. The investigators call this the QZ563 cohort. Within it, a subset of 391 patients carried detailed clinicopathologic, biomarker, treatment, and survival information, forming the Clinical391 cohort used for deeper outcome analyses. By layering somatic mutations, tumor mutational burden, microsatellite instability status, metastatic patterns, and treatment-related biomarkers onto this clinical foundation, the team built a multidimensional map of advanced gastric cancer as it actually presents in Chinese hospitals.

The mutational landscape that emerged was dominated by familiar names. TP53 was altered in 70.8 percent of tumors, cementing its role as the single most frequently disrupted gene in advanced gastric cancer. Alongside it, ARID1A, CDH1, and PIK3CA ranked among the most commonly mutated genes, a pattern consistent with prior genomic surveys of the disease. But the study’s real contribution lies not in cataloging the usual suspects. Instead, the researchers asked how clinically actionable biomarkers carve up the patient population, and whether the resulting categories carry meaningful biological and prognostic differences that standard staging alone cannot capture.

One of the most clinically consequential findings concerns a small but important subgroup: patients whose tumors lack any of the established treatment-related biomarkers. The team labeled this group treatment-biomarker-negative gastric cancer, and their analysis revealed that these tumors are molecularly heterogeneous rather than uniformly indolent or uniformly aggressive. In other words, patients who test negative for actionable markers are not a single biological entity; they represent a mixed collection of genomic states that current biomarker panels do not resolve. The authors are careful to note that this subgroup warrants further validation, but the implication is provocative. A negative biomarker result may conceal as much biological diversity as a positive one, and refining how these patients are characterized could eventually open new therapeutic doors.

Metastatic phenotype added another layer of clinically relevant heterogeneity. By comparing tumors from patients with peritoneal involvement against those with liver metastases, the researchers identified distinct patterns of pathway-level mutation preference, suggesting that the route a gastric cancer takes when it spreads is written, at least in part, into its genome. This distinction matters because peritoneal and liver metastases carry different prognoses and respond differently to systemic therapy. A genomic framework that recognizes metastatic phenotype as a biologically meaningful axis, rather than a mere anatomical detail, could help clinicians anticipate disease trajectories and select treatments more rationally for stage IV patients.

The study’s most striking molecular discovery, however, centers on two chromatin-regulating genes: KMT2C and KMT2D. Loss-of-function alterations in these genes, which disrupt histone methyltransferase complexes that help orchestrate gene expression, were present in 6.4 percent of the QZ563 cohort. That modest frequency conceals a dramatic association. Among tumors carrying KMT2C or KMT2D loss-of-function changes, 48.3 percent were microsatellite instability-high, compared with just 2.7 percent of tumors lacking these alterations, a difference the authors report as highly statistically significant. In plain terms, when the epigenetic machinery governed by KMT2C and KMT2D breaks down, the genome’s mismatch repair system appears far more likely to falter as well, unleashing the mutational storm that defines MSI-high disease.

Crucially, the association did not stop at microsatellite status. Within both microsatellite-stable and MSI-high strata, KMT2C/D loss-of-function tumors showed higher tumor mutational burden than their wild-type counterparts, indicating that these chromatin alterations push genomic instability upward even within established MSI categories. The researchers then cross-checked this pattern against The Cancer Genome Atlas stomach adenocarcinoma dataset, known as TCGA-STAD, and found the same molecular signature, lending independent support to the finding. Yet a cautionary note accompanies the excitement: KMT2C/D loss-of-function status was not associated with a survival benefit in this cohort. High mutational burden is often assumed to predict better responses to immunotherapy, but the data here suggest that KMT2C/D-linked hypermutation alone does not translate into improved outcomes, at least within this retrospective framework.

To move from association toward therapeutic hypothesis, the team turned to DepMap, a large-scale cancer dependency resource that catalogs which genes cancer cell lines cannot survive without. Their analyses nominated WRN, a DNA helicase gene, as a candidate dependency in KMT2C/D loss-of-function MSI models. WRN dependency in MSI-high cancers has emerged in recent years as one of the most tantalizing synthetic lethal opportunities in oncology, and this study extends that concept into the KMT2C/D-altered subset. The authors are explicit that this remains hypothesis-generating and requires functional validation before any clinical translation, but the nomination of a druggable vulnerability within a molecularly defined subgroup exemplifies how large clinical-genomic datasets can seed the next generation of precision trials.

The study also integrated transcriptomic data from TCGA-STAD to probe what KMT2C/D loss-of-function means biologically within the MSI background, examining immune-related and non-immune signature scores between altered and wild-type tumors. Sensitivity analyses confirmed the directional concordance of co-mutation patterns between the Chinese cohort and TCGA, and the researchers stratified their TMB comparisons by MSI status to ensure the association was not simply an artifact of hypermutation. Methodologically, the work illustrates the value of pairing a well-annotated single-institution cohort with public genomic resources: the clinical depth of the Chinese data anchors the findings in real-world patient care, while the external datasets guard against cohort-specific artifacts.

For patients and clinicians, the takeaway is twofold. First, biomarker testing in advanced gastric cancer is not merely a pass-fail gate; the clinical and genomic context surrounding a biomarker result, including metastatic pattern and chromatin gene status, carries information that current decision trees largely ignore. Second, the KMT2C/D-MSI axis offers a potential new lens for subdividing the immunotherapy-sensitive population, one that could eventually explain why some hypermutated tumors respond spectacularly to checkpoint inhibitors while others do not. The study, approved by the Ethics Committee of Peking University Cancer Hospital and funded by Chinese national and municipal science programs, is retrospective by design, and the authors themselves frame the WRN finding as requiring experimental confirmation. Even so, in a disease where one in five patients may harbor molecular features invisible to standard panels, this 563-patient genomic atlas marks a meaningful step toward treatment maps that reflect the full genetic complexity of gastric cancer.

Subject of Research: Clinical-genomic stratification of treatment biomarkers and KMT2C/D-associated microsatellite instability heterogeneity in advanced Chinese gastric cancer

Article Title: Clinical-genomic stratification of treatment biomarkers and KMT2C/D-linked MSI heterogeneity in Chinese gastric cancer: a retrospective cohort study

Article References: Yu, C., Liu, S., Zhou, Z., Qin, N., Yang, L., Wang, J., Ding, M., Chong, X., Wang, Y., & Zhang, X. (2026). Clinical-genomic stratification of treatment biomarkers and KMT2C/D-linked MSI heterogeneity in Chinese gastric cancer: a retrospective cohort study. BMC Cancer. https://doi.org/10.1186/s12885-026-17051-6

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17051-6

Keywords: gastric cancer, KMT2C, KMT2D, microsatellite instability, tumor mutational burden, WRN dependency, treatment biomarkers, tumor heterogeneity, precision oncology, targeted therapy, immunotherapy biomarkers, retrospective cohort study

The research team turned to spatial transcriptomics, a technology that measures gene expression across intact tissue sections while preserving the physical coordinates of every measurement. Unlike single-cell RNA sequencing, which dissociates tissue and loses positional information, spatial transcriptomics allows researchers to ask not only which genes are active, but where. The investigators applied this approach to tumor samples containing TLS and used a computational framework called EcoTyper to infer cell states — transcriptionally coherent subpopulations within broader cell lineages — directly from the spatial data. In total, they identified 71 distinct cell states spanning all of the major immune lineages present in the tumor microenvironment, from B cells and T cells to dendritic cells and neutrophils.

This cell state-level resolution proved to be the study’s decisive methodological choice. When the researchers examined how each inferred state was distributed along a gradient running from the geometric core of a TLS to its surrounding periphery, they found that cells belonging to the same lineage could behave in dramatically different ways. Some lineages contained states that were enriched within the TLS and others that were depleted there, meaning that a coarse analysis lumping all cells of a lineage together would have averaged away the very patterns the researchers were seeking. Core-periphery organization, the authors conclude, is in an important sense invisible at the cell type level and only emerges at the cell state level.

Among the most notable discoveries were two TLS-enriched CD4 T cell states with clearly distinct marker gene programs. Although both belonged to the helper T cell lineage and both accumulated within tertiary lymphoid structures, they carried different transcriptional signatures, suggesting they perform different functions within the immune hub. One of these states, designated CD4.T_S02, was more abundant toward the geometric core of the TLS, while its counterpart occupied more peripheral positions. This kind of fine-grained spatial segregation within a single lineage hints at a division of labor inside TLS that mirrors, in miniature, the zoned organization of canonical lymphoid organs such as lymph nodes and the spleen.

To complement the abundance-gradient analysis, the team constructed weighted chemokine networks centered on three key signaling molecules: CXCL13, CXCL12, and the paired chemokines CCL19 and CCL21. Chemokines are the trafficking signals of the immune system, guiding cells to their destinations through gradients and receptor-ligand matching. CXCL13 and CCL19/21 are classically associated with lymphoid organization — they recruit B cells and helper T cells into structured aggregates and help maintain the boundary between distinct lymphoid zones — while CXCL12 has been implicated in both lymphoid organization and immunosuppressive niches. By mapping how these chemokine signals relate to the inferred cell states across space, the researchers could ask whether the transcriptional picture of TLS organization was corroborated by an independent, signaling-centered lens.

It was. The chemokine network analysis revealed two recurrent communities of cell states. The first was a lymphocyte activation community confined to the TLS themselves, consistent with the idea that the core of these structures is where immune cells are being primed and activated. The second was an effector-focused community that extended outward into the surrounding tumor tissue, suggesting that TLS do not merely house immune activity but actively export it — dispatching armed effector cells into the tumor proper, where they can encounter and attack malignant cells. This core-to-periphery functional gradient provides a mechanistic rationale for the clinical association between TLS presence and better outcomes: a tumor with well-organized TLS is not just decorated with immune cells, it is plugged into a production line for antitumor immunity.

One of the most intriguing recurring characters in this spatial drama was a neutrophil cell state of tentative identity that appeared as a hub across all three chemokine axes the researchers examined. Neutrophils are usually cast as short-lived, blunt instruments of innate immunity, and in many tumors they are associated with immunosuppression. The repeated emergence of a neutrophil state at the center of TLS-associated chemokine networks raises the possibility that a specialized neutrophil population may play an architectural or regulatory role within these structures — perhaps helping to organize the recruitment of lymphocytes, or modulating the signals that keep the TLS intact. The authors are careful to label this state’s identity as tentative, and defining it precisely will be a task for future work, but its centrality across independent analyses makes it one of the study’s most provocative leads.

Taken together, the two analytical strategies — the TLS-centric abundance gradient and the weighted chemokine networks — converge on a coherent model. Tertiary lymphoid structures, in this view, are spatially zoned organs: an active core where lymphocyte activation and germinal center-like processes dominate, surrounded by a more diffuse effector periphery where armed immune cells transition into the tumor tissue. The zones are not arbitrary; they are organized through a shared, key set of chemokine signaling pathways, with CXCL13, CXCL12, and CCL19/21 acting as the molecular mortar that holds the architecture in place. This zoned model reframes TLS from static histological features into dynamic, functionally compartmentalized machines for generating and deploying antitumor immunity.

The implications for cancer medicine are considerable. TLS are already the subject of intense interest as biomarkers for immunotherapy response, and numerous clinical efforts aim to induce or mature them in tumors that lack them. The new findings suggest that such efforts should be evaluated not simply by whether TLS appear, but by whether they acquire the correct internal organization — the right cell states in the right places, wired together by the right chemokine signals. A disorganized aggregate of lymphocytes may not function like a properly zoned TLS, and therapies that reshape chemokine signaling could, in principle, convert poorly structured infiltrates into fully functional immune hubs. The cell state atlas generated in this study offers a reference against which such interventions could be measured.

The study, conducted under ethics approvals from the University of Tokyo and Keio University School of Medicine and supported by JSPS KAKENHI grants, also demonstrates the maturing of spatial transcriptomics as a discovery platform. By combining computational state inference with explicit spatial modeling and network analysis, the researchers extracted organizational principles that neither approach alone would have revealed. As the technology spreads and atlases of this kind accumulate across cancer types, the field moves closer to a genuinely spatial understanding of the tumor immune microenvironment — one in which the arrangement of cells, not merely their presence, becomes a target of measurement, prediction, and ultimately therapy. For now, the message of this work is clear: to understand how tumors’ hidden immune organs work, one must look not just at who is there, but at who is where, and at the chemical conversations that put them there.

Subject of Research: Spatial organization and chemokine network architecture of tertiary lymphoid structures in tumors

Article Title: Spatial transcriptomics reveals cell state-level organization and chemokine network architecture within tertiary lymphoid structures

Article References: Yan, A., Iwasawa, T., Tanaka, N., Kakimi, K., Lysenko, A., & Tsunoda, T. (2026). Spatial transcriptomics reveals cell state-level organization and chemokine network architecture within tertiary lymphoid structures. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04529-2

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04529-2

Keywords: tertiary lymphoid structures, spatial transcriptomics, chemokine signaling networks, cell states, tumor microenvironment, cancer immunology, CXCL13, CXCL12, CCL19, CD4 T cells, neutrophils, immunotherapy biomarkers